Almost a year to the day after Roche pulled out a partnership on its underperforming cancer therapy Gavreto, Blueprint Medicines has sold US commercial rights to the drug to Rigel Pharma in a deal ...
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The ...
**NM signifies a non meaningful value. A dash signifies the data is not available.
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results